Hormonal therapy in metastatic prostate cancer: current perspectives and controversies

about

Hormonal therapy in metastatic prostate cancer: current perspectives and controversies

Item

http://www.wikidata.org/entity/Q35569303

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

2013年论文

@zh

2013年论文

@zh-cn

name

Hormonal therapy in metastatic prostate cancer: current perspectives and controversies

@ast

Hormonal therapy in metastatic prostate cancer: current perspectives and controversies

@en

type

Item

label

Hormonal therapy in metastatic prostate cancer: current perspectives and controversies

@ast

Hormonal therapy in metastatic prostate cancer: current perspectives and controversies

@en

prefLabel

Hormonal therapy in metastatic prostate cancer: current perspectives and controversies

@ast

Hormonal therapy in metastatic prostate cancer: current perspectives and controversies

@en

P1476

Hormonal therapy in metastatic prostate cancer: current perspectives and controversies

@en

P2093

Manish Garg

http://www.w3.org/2001/XMLSchema#string

Manoj Kumar

http://www.w3.org/2001/XMLSchema#string

Satya Narayan Sankhwar

http://www.w3.org/2001/XMLSchema#string

Vishwajeet Singh

http://www.w3.org/2001/XMLSchema#string

P2860

Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study

Development of a second-generation antiandrogen for treatment of advanced prostate cancer

Androgen deprivation therapy in the treatment of advanced prostate cancer

CYP17 inhibitors for prostate cancer therapy

Increased survival with enzalutamide in prostate cancer after chemotherapy

Abiraterone and increased survival in metastatic prostate cancer

Effect of dutasteride on the risk of prostate cancer.

Tolerability of Nonsteroidal Antiandrogens in the Treatment of Advanced Prostate Cancer.

Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy.

Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate

P304

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.4081/ONCOL.2013.E6

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2013-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

277084701

http://www.w3.org/2001/XMLSchema#string

P698

25992227

http://www.w3.org/2001/XMLSchema#string

P932

4419613

http://www.w3.org/2001/XMLSchema#string